Charles River Laboratories Price to Sales Ratio 2010-2024 | CRL
Historical PS ratio values for Charles River Laboratories (CRL) over the last 10 years. The current P/S ratio for Charles River Laboratories as of December 27, 2024 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Charles River Laboratories P/S Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Sales per Share | Price to Sales Ratio |
| 2024-12-27 | 186.16 | 2.37 | |
| 2024-09-30 | 196.97 | $78.58 | 2.51 |
| 2024-06-30 | 206.58 | $78.89 | 2.62 |
| 2024-03-31 | 270.95 | $79.70 | 3.40 |
| 2023-12-31 | 236.40 | $80.20 | 2.95 |
| 2023-09-30 | 195.98 | $81.94 | 2.39 |
| 2023-06-30 | 210.25 | $81.34 | 2.58 |
| 2023-03-31 | 201.82 | $79.72 | 2.53 |
| 2022-12-31 | 217.90 | $77.51 | 2.81 |
| 2022-09-30 | 196.80 | $73.67 | 2.67 |
| 2022-06-30 | 213.97 | $71.76 | 2.98 |
| 2022-03-31 | 283.97 | $70.60 | 4.02 |
| 2021-12-31 | 376.78 | $68.94 | 5.47 |
| 2021-09-30 | 412.67 | $66.97 | 6.16 |
| 2021-06-30 | 369.92 | $64.25 | 5.76 |
| 2021-03-31 | 289.83 | $60.02 | 4.83 |
| 2020-12-31 | 249.86 | $58.02 | 4.31 |
| 2020-09-30 | 226.45 | $56.30 | 4.02 |
| 2020-06-30 | 174.35 | $55.08 | 3.17 |
| 2020-03-31 | 126.21 | $54.74 | 2.31 |
| 2019-12-31 | 152.76 | $52.81 | 2.89 |
| 2019-09-30 | 132.37 | $51.17 | 2.59 |
| 2019-06-30 | 141.90 | $49.60 | 2.86 |
| 2019-03-31 | 145.25 | $48.29 | 3.01 |
| 2018-12-31 | 113.18 | $46.19 | 2.45 |
| 2018-09-30 | 134.54 | $43.77 | 3.07 |
| 2018-06-30 | 112.26 | $41.50 | 2.71 |
| 2018-03-31 | 106.74 | $39.27 | 2.72 |
| 2017-12-31 | 109.45 | $38.36 | 2.85 |
| 2017-09-30 | 108.02 | $38.24 | 2.82 |
| 2017-06-30 | 101.15 | $37.51 | 2.70 |
| 2017-03-31 | 89.95 | $36.86 | 2.44 |
| 2016-12-31 | 76.19 | $35.11 | 2.17 |
| 2016-09-30 | 83.34 | $32.80 | 2.54 |
| 2016-06-30 | 82.44 | $31.34 | 2.63 |
| 2016-03-31 | 75.94 | $29.42 | 2.58 |
| 2015-12-31 | 80.39 | $28.66 | 2.80 |
| 2015-09-30 | 63.52 | $28.16 | 2.26 |
| 2015-06-30 | 70.34 | $27.75 | 2.53 |
| 2015-03-31 | 79.29 | $27.77 | 2.86 |
| 2014-12-31 | 63.64 | $27.29 | 2.33 |
| 2014-09-30 | 59.74 | $26.32 | 2.27 |
| 2014-06-30 | 53.52 | $25.37 | 2.11 |
| 2014-03-31 | 60.34 | $24.21 | 2.49 |
| 2013-12-31 | 53.04 | $24.01 | 2.21 |
| 2013-09-30 | 46.26 | $23.83 | 1.94 |
| 2013-06-30 | 41.03 | $23.59 | 1.74 |
| 2013-03-31 | 44.27 | $23.47 | 1.89 |
| 2012-12-31 | 37.47 | $23.32 | 1.61 |
| 2012-09-30 | 39.60 | $23.21 | 1.71 |
| 2012-06-30 | 32.76 | $22.91 | 1.43 |
| 2012-03-31 | 36.09 | $22.60 | 1.60 |
| 2011-12-31 | 27.33 | $21.98 | 1.24 |
| 2011-09-30 | 28.62 | $20.81 | 1.38 |
| 2011-06-30 | 40.65 | $19.64 | 2.07 |
| 2011-03-31 | 38.38 | $18.45 | 2.08 |
| 2010-12-31 | 35.54 | $17.65 | 2.01 |
| 2010-09-30 | 33.15 | $17.18 | 1.93 |
| 2010-06-30 | 34.21 | $17.40 | 1.97 |
| 2010-03-31 | 39.31 | $17.74 | 2.22 |
| 2009-12-31 | 33.69 | $17.87 | 1.89 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $9.545B | $4.129B |
| Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $86.660B | 10.75 |
| Cencora (COR) | United States | $43.795B | 16.47 |
| DiDi Global (DIDIY) | China | $22.310B | 0.00 |
| Natera (NTRA) | United States | $21.076B | 0.00 |
| ICON (ICLR) | Ireland | $17.639B | 15.71 |
| Viatris (VTRS) | United States | $14.992B | 4.62 |
| Avantor (AVTR) | United States | $14.620B | 21.92 |
| Revvity (RVTY) | United States | $13.691B | 23.78 |
| BioMerieux (BMXMF) | France | $12.233B | 0.00 |
| CochLear (CHEOY) | Australia | $12.042B | 0.00 |
| Solventum (SOLV) | United States | $11.564B | 0.00 |
| Doximity (DOCS) | United States | $10.907B | 64.20 |
| Medpace Holdings (MEDP) | United States | $10.659B | 30.03 |
| HealthEquity (HQY) | United States | $8.442B | 42.35 |
| Sonic Healthcare (SKHHY) | Australia | $8.258B | 0.00 |
| Bausch + Lomb (BLCO) | Canada | $6.388B | 29.74 |
| Amplifon S.p.A (AMFPF) | Italy | $5.864B | 29.89 |
| Organon (OGN) | United States | $3.850B | 3.88 |
| Sotera Health (SHC) | United States | $3.827B | 20.47 |
| BrightSpring Health Services (BTSG) | United States | $3.065B | 65.18 |
| Surgery Partners (SGRY) | United States | $2.716B | 30.97 |
| Concentras Parent (CON) | United States | $2.623B | 0.00 |
| Ardent Health Partners (ARDT) | United States | $2.382B | 0.00 |
| GeneDx Holdings (WGS) | United States | $2.183B | 0.00 |
| Premier (PINC) | United States | $2.090B | 10.88 |
| Alignment Healthcare (ALHC) | United States | $2.078B | 0.00 |
| PACS (PACS) | United States | $2.009B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.723B | 45.20 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.651B | 0.00 |
| Teladoc Health (TDOC) | United States | $1.641B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.295B | 0.00 | |
| Progyny (PGNY) | United States | $1.253B | 25.36 |
| Embecta (EMBC) | United States | $1.211B | 8.47 |
| Pediatrix Medical (MD) | United States | $1.173B | 11.48 |
| CareDx (CDNA) | United States | $1.150B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $0.918B | 6.21 |
| QDM (QDMI) | Hong Kong, SAR China | $0.790B | 20.69 |
| Agilon Health (AGL) | United States | $0.779B | 0.00 |
| SBC Medicals (SBC) | United States | $0.604B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.549B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.496B | 0.00 |
| DocGo (DCGO) | United States | $0.447B | 16.85 |
| Sonida Senior Living (SNDA) | United States | $0.442B | 0.00 |
| Enhabit (EHAB) | United States | $0.389B | 33.61 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.283B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.274B | 0.00 |
| LifeMD (LFMD) | United States | $0.230B | 0.00 |
| Biodesix (BDSX) | United States | $0.212B | 0.00 |
| MultiPlan (MPLN) | United States | $0.203B | 0.00 |
| Beauty Health (SKIN) | United States | $0.195B | 0.00 |
| Nutex Health (NUTX) | United States | $0.179B | 0.00 |
| ModivCare (MODV) | United States | $0.157B | 8.53 |
| So-Young (SY) | China | $0.099B | 16.74 |
| Ascend Wellness Holdings (AAWH) | United States | $0.078B | 0.00 |
| NeueHealth (NEUE) | United States | $0.060B | 1.59 |
| IceCure Medical (ICCM) | Israel | $0.051B | 0.00 |
| Singular Genomics Systems (OMIC) | United States | $0.049B | 0.00 |
| OncoCyte (OCX) | United States | $0.036B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.027B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.027B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.024B | 0.00 |
| Oncology Institute (TOI) | United States | $0.020B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.009B | 0.00 |
| XWELL (XWEL) | United States | $0.008B | 0.00 |
| KindlyMD (KDLY) | United States | $0.007B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.006B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.004B | 0.00 | |
| NewGenIvf Group (NIVF) | Thailand | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| Aclarion (ACON) | United States | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.001B | 0.00 |